Close Menu

phase I clinical study

Strata will use its StrataNGS profiling test to identify patients with advanced solid tumors harboring KRAS G12C mutations for enrollment into Mirati's KRYSTAL-1 trial.

Natera's Signatera test will be used to select and monitor eligible patients with KRAS-mutant tumors who have molecular residual disease after surgery.

Roche is developing an immunohistochemnistry assay for Pierre Fabre's oncology drug candidate, an antibody drug conjugate targeting insulin-like growth factor 1 receptor.